Inotiv Inc. – 10/24/2025. Country: United States. Record Type: 483
Similar Posts
Compounding and the FDA: Questions and Answers
Creating a medication tailored to the needs of an individual patient. FDA answers the “what” and “why” of compounding. From consumers to health care professionals, there are many questions about compounding. FDA works to answer questions related to the meaning, intent and requirements of compoundingAfrica Imports Issues Voluntary Recall of Organic Moringa Leaf Powder Due to Potential Salmonella Contamination
Africa Imports is voluntarily recalling its Organic Moringa Leaf Powder (1 kilogram box) because it may be contaminated with Salmonella, an organism that can cause serious and sometimes fatal infections in young children, the elderly, and individuals with weakened immune systems. Healthy persons infNovel Drug Approvals for 2026
Novel Drug Approvals for 2026Central Admixture Pharmacy Services Inc. Allentown, PA. 483 issued 09/05/2025
Task Description Request Please post to the OII FOIA Electronic Reading Room
Record Date 09/05/2025
Short Title (70 char) Central Admixture Pharmacy Services Inc. Allentown, PA. 483 issued 09/05/2025
FEI Number 3009590582
Firm Name Central Admixture Pharmacy Services Inc
Record Type 483
State PA
EstPeakMax may be harmful due to hidden drug ingredients
The Food and Drug Administration is advising consumers not to purchase or use PeakMax, a product promoted and sold for sexual enhancement on various websites, including www.vitalityvita.com, and possibly in some retail stores.Model-Informed Drug Development Paired Meeting Program
FDA is conducting a MIDD Pilot Program to facilitate the development and application of exposure-based, biological, and statistical models derived from preclinical and clinical data sources, referred to as MIDD approaches.